Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, China.
Clin Epigenetics. 2019 Aug 1;11(1):112. doi: 10.1186/s13148-019-0711-4.
SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) and MYND (Myeloid-Nervy-DEAF1) domain-containing protein 2 (SMYD2) is a protein methyltransferase that methylates histone H3 at lysine 4 (H3K4) or lysine 36 (H3K36) and diverse nonhistone proteins. SMYD2 activity is required for normal organismal development and the regulation of a series of pathophysiological processes. Since aberrant SMYD2 expression and its dysfunction are often closely related to multiple diseases, SMYD2 is a promising candidate for the treatment of these diseases, such as cardiovascular disease and cancer. Here, we present an overview of the complex biology of SMYD2 and its family members and their context-dependent nature. Then, we discuss the discovery, structure, inhibitors, roles, and molecular mechanisms of SMYD2 in distinct diseases, with a focus on cardiovascular disease and cancer.
SET（绝缘子，增强子的结合锌指蛋白，果蝇Trithorax）和 MYND（髓系-神经-耳聋 1）结构域蛋白 2（SMYD2）是一种组蛋白甲基转移酶，它可以使组蛋白 H3 赖氨酸 4（H3K4）或赖氨酸 36（H3K36）和多种非组蛋白蛋白甲基化。SMYD2 的活性对于正常的机体发育和一系列病理生理过程的调节是必需的。由于异常的 SMYD2 表达及其功能障碍通常与多种疾病密切相关，SMYD2 是治疗这些疾病（如心血管疾病和癌症）的有前途的候选药物。在这里，我们对 SMYD2 及其家族成员的复杂生物学及其上下文相关性质进行了概述。然后，我们讨论了 SMYD2 在不同疾病中的发现、结构、抑制剂、作用和分子机制，重点是心血管疾病和癌症。
